Evidence map›Paper›PMID 36139533›Full record

ArticleCancers2022

Mitochondrial Protein Cox7b Is a Metabolic Sensor Driving Brain-Specific Metastasis of Human Breast Cancer Cells.

Marine C N M Blackman, Tania Capeloa, Justin D Rondeau, Luca X Zampieri, Zohra Benyahia, Justine A Van de Velde, Maude Fransolet, Evangelos P Daskalopoulos, Carine Michiels, Christophe Beauloye and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Metabolic adaptations of brain metastasis.Nature reviews. Cancer · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Marine C N M BlackmanPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.ORCID 0000-0002-8392-4094
Tania CapeloaPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.ORCID 0000-0001-8034-5524
Justin D RondeauPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.
Luca X ZampieriPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.ORCID 0000-0002-9286-7693
Zohra BenyahiaPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.
Justine A Van de VeldePole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.
Maude FransoletURBC-NARILIS, University of Namur, 5000 Namur, Belgium.
Evangelos P DaskalopoulosPole of Cardiology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 55 Box B1.55.05, 1200 Brussels, Belgium.ORCID 0000-0003-0543-605X
Carine MichielsURBC-NARILIS, University of Namur, 5000 Namur, Belgium.ORCID 0000-0002-9169-1294
Christophe BeauloyePole of Cardiology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 55 Box B1.55.05, 1200 Brussels, Belgium.
Pierre SonveauxPole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 57 Box B1.53.09, 1200 Brussels, Belgium.ORCID 0000-0001-6484-8834
Walloon Excellence in Lifesciences and Biotechnology · BEUCLouvain · BEUniversity of Namur · BE

Funding

European Union's Horizon 2020 research innovation program Marie Skłodowska-Curie grant agreements No 722605 TRANSMITFund for Scientific Research CDR J.0135.18, CDR J.0177.22Télévie project n°7.4529.17Walloon Excellence in Lifesciences and Biotechnology WELBIO-CR-2022A-13
6 · The paper itself

Abstract

Distant metastases are detrimental for cancer patients, but the increasingly early detection of tumors offers a chance for metastasis prevention. Importantly, cancers do not metastasize randomly: depending on the type of cancer, metastatic progenitor cells have a predilection for well-defined organs. This has been theorized by Stephen Paget, who proposed the "seed-and-soil hypothesis", according to which metastatic colonization occurs only when the needs of a given metastatic progenitor cell (the seed) match with the resources provided by a given organ (the soil). Here, we propose to explore the seed-and-soil hypothesis in the context of cancer metabolism, thus hypothesizing that metastatic progenitor cells must be capable of detecting the availability of metabolic resources in order to home in a secondary organ. If true, it would imply the existence of metabolic sensors. Using human triple-negative MDA-MB-231 breast cancer cells and two independent brain-seeking variants as models, we report that cyclooxygenase 7b (Cox7b), a structural component of Complex IV of the mitochondrial electron transport chain, belongs to a probably larger family of proteins responsible for breast cancer brain tropism in mice. For metastasis prevention therapy, this proof-of-principle study opens a quest for the identification of therapeutically targetable metabolic sensors that drive cancer organotropism.

Indexed as

brain metastasisbreast cancercancer metabolismcyclooxygenase 7b (Cox7b)mitochondriaorganotropismoxidative phosphorylation (OXPHOS)tissue-specific metastasis

Identifiers

PMID36139533
PMCPMC9497206
OpenAlexW4296087415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.